Scholarlink

Purpose <p>To assess and compare the diagnostic performance of Gallium-68 DOTA-Tyr<sup>3</sup>-octreotate positron emission tomography/computed tomography (<sup>68</sup>Ga-DOTATATE PET/CT) and Iodine-123 metaiodobenzylguanidine single photon emission computed tomography/computed tomography (<sup>123</sup>I-MIBG SPECT/CT) in detecting central nervous system (CNS) metastases of neuroblastoma (NB) and ganglioneuroblastoma (GNB), as well as to evaluate their impact on therapeutic management.</p> Methods <p>This prospective study enrolled 41 patients with NB and GNB who were suspected of having CNS metastases. All patients underwent paired <sup>123</sup>I-MIBG SPECT/CT and <sup>68</sup>Ga-DOTATATE PET/CT imaging within 1 week (median: 3 days; range: 1–7 days). The diagnostic performance of the two imaging modalities was assessed and compared on a per-patient, per-lesion and per-region basis. Furthermore, the differences in patient characteristics between groups with and without changes in clinical management decisions were analyzed. Group differences were evaluated using the independent samples t-test, χ<sup>2</sup> test, Fisher’s exact test, and Mann-Whitney U test.</p> Results <p>40 patients (40/41, 98%) were confirmed with CNS metastases. The mean age at CNS metastases was 63 months (range: 8-122 months). <sup>68</sup>Ga-DOTATATE PET/CT exhibited superior performance compared with <sup>123</sup>I-MIBG SPECT/CT in detecting CNS metastases on a per-patient, per-lesion and per-region basis. Additionally, the results of <sup>68</sup>Ga-DOTATATE PET/CT led to changes in clinical management in 51% (21/41) of patients, primarily due to new or unexpected findings compared with those obtained using <sup>123</sup>I-MIBG SPECT/CT.</p> Conclusions <p><sup>68</sup>Ga-DOTATATE PET/CT demonstrated excellent diagnostic performance in NB and GNB patients with CNS metastases. Moreover, the findings from <sup>68</sup>Ga-DOTATATE PET/CT led to a modification of the therapeutic management in 51% of patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A head-to-head prospective comparative analysis of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT/CT in central nervous system metastases of neuroblastoma and ganglioneuroblastoma

  • 期刊论文

  • 发表日期：

    2025年7月10日

查看全文
  • Siqi Li,
  • Ziang Zhou,
  • Xiaoya Wang,
  • Yanfeng Xu,
  • Wei Wang,
  • Jun Liu,
  • Jigang Yang

摘要

Purpose

To assess and compare the diagnostic performance of Gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography (68Ga-DOTATATE PET/CT) and Iodine-123 metaiodobenzylguanidine single photon emission computed tomography/computed tomography (123I-MIBG SPECT/CT) in detecting central nervous system (CNS) metastases of neuroblastoma (NB) and ganglioneuroblastoma (GNB), as well as to evaluate their impact on therapeutic management.

Methods

This prospective study enrolled 41 patients with NB and GNB who were suspected of having CNS metastases. All patients underwent paired 123I-MIBG SPECT/CT and 68Ga-DOTATATE PET/CT imaging within 1 week (median: 3 days; range: 1–7 days). The diagnostic performance of the two imaging modalities was assessed and compared on a per-patient, per-lesion and per-region basis. Furthermore, the differences in patient characteristics between groups with and without changes in clinical management decisions were analyzed. Group differences were evaluated using the independent samples t-test, χ2 test, Fisher’s exact test, and Mann-Whitney U test.

Results

40 patients (40/41, 98%) were confirmed with CNS metastases. The mean age at CNS metastases was 63 months (range: 8-122 months). 68Ga-DOTATATE PET/CT exhibited superior performance compared with 123I-MIBG SPECT/CT in detecting CNS metastases on a per-patient, per-lesion and per-region basis. Additionally, the results of 68Ga-DOTATATE PET/CT led to changes in clinical management in 51% (21/41) of patients, primarily due to new or unexpected findings compared with those obtained using 123I-MIBG SPECT/CT.

Conclusions

68Ga-DOTATATE PET/CT demonstrated excellent diagnostic performance in NB and GNB patients with CNS metastases. Moreover, the findings from 68Ga-DOTATATE PET/CT led to a modification of the therapeutic management in 51% of patients.